Alnylam and Spectrum both name new chief medical officers

Two US biotechnology companies, Alnylam Pharmaceuticals (Nasdaq: ALNY) and Spectrum Pharmaceuticals (NasdaqGS: SPPI) both yesterday announced new heads of medical affairs, as well as another appointment at the latter firm.

Alnylam, a leading RNAi therapeutics company, said it has promoted Akshay Vaishnaw to the new position of chief medical officer. Dr Vaishnaw previously held the title of senior vice president, Clinical Research.

He has led the advancement of Alnylam’s pipeline and has aptly earned this promotion and new recognition,” said chief executive John Maraganore, adding: “Alnylam is leading the development of RNAi therapeutics as innovative medicines. With three programs in human clinical trials currently and a total of five expected by year’s end, Akshay’s leadership has been instrumental in the transformation of our business from a platform company to a product company.”